The Globe and Mail Jameson Berkow Published March 2, 2021
Moha El-Jaw/iStockPhoto / Getty Images
Could the burgeoning psychedelics sector end up spawning a major stock rally that could dwarf the cannabis-driven market mayhem of the past decade?
According to Maruf Raza, a partner and national director of public companies at MNP LLP in Toronto, “From a market perspective, you could argue the blue-sky opportunity for psychedelics is far, far greater [than for cannabis].”
Mr. Raza is part of a growing group of market watchers expecting vast sums of money to pour into companies studying psilocybin, ketamine, LSD and other so-called “hard drugs” for medical purposes. But because the nascent sector is largely organized around disrupting the global anti-depressant market, which is worth tens of billions of dollars annually to pharmaceutical giants, investors see less policy risk.
MagicMed | Benzinga benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
The psychedelics market is growing, as more jurisdictions legalize or decriminalize different form of them.
In this context, Shelby Hartman and Madison Margolin are launching DoubleBlind, a biannual print magazine and digital media company focused on psychedelics.
Contributors around the world will. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
This article was originally published on Microdose Psychedelic Insights, and appears here with permission.
Recent figures estimate that the abuse of tobacco, alcohol, and drugs within the United States totals to over $1 trillion dollars a year in costs and counting.1 Between the. Read More.
While the tumultuous year that was 2020 brought numerous unforeseen challenges with it, psychedelic medicine made remarkable progress. With the new year in full swing, psychedelic companies are continuing to make their debut on the stock exchanges, making their mark on capital markets. After a fortuitous conference series in 2020, Psychedelic Capital, the premiere psychedelic due diligence conference, returns to highlight dignitaries from the top companies in the space.
The First Psychedelic Capital of 2021 Features Innovative Sponsors and Speakers
The first Psychedelic Capital event of 2021 is on January 28th at 4:30pm EST and will feature engaging presentations from our sponsors, Psygen Labs, Albert Labs and Mindset Pharma.